GlassScriptPhysician profile
Dennis Reison
NPI 1316943483
$5,020.36
in general payments reported to CMS, 2019-2025
35 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $432 · 2021: $657 · 2022: $1,141 · 2023: $605 · 2024: $433 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $567.05 | 2019-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.58 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $437.35 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $379.08 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $329.31 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $290.88 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $272.03 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $258.87 | 2019-2024 | |
| Abiomed | $257.49 | 2019-2025 | Impella |
| Arbor Pharmaceuticals, INC. | $206.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $203.34 | 2019-2023 | Livalo |
| Cardiva Medical, INC. | $176.93 | 2021-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boston Scientific Corporation | $156.53 | 2021-2024 | Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $108.86 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $101.14 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $100.51 | 2021-2024 | Verquvo |
| Cvrx, INC. | $97.47 | 2022-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $74.26 | 2019-2022 | |
| Gilead Sciences, INC. | $43.07 | 2019 | |
| Novo Nordisk INC | $42.25 | 2021-2024 | Rybelsus, Ozempic |
| Shockwave Medical, INC | $31.54 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Penumbra, INC. | $30.83 | 2022 | |
| Terumo Medical Corporation | $26.46 | 2025 | Glidewire, Metacross Otw |
| Esperion Therapeutics, INC. | $26.30 | 2020-2022 | |
| Preventice Services, LLC | $25.00 | 2019 | |
| Heartflow, INC. | $23.82 | 2025 | |
| Medtronic, INC. | $20.53 | 2022 | |
| Bardy Diagnostics, INC. | $19.84 | 2020 | |
| Portola Pharmaceuticals, LLC | $15.54 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.55 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $13.77 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.85 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.27 | 2019 | |
| Irhythm Technologies, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Reison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.